AU2005289169B2 - Novel crystalline form of (3-cyano-1H-indol-7-yl)-[4-(4-fluorophenethyl)-piperazine-1-yl]-methanone hydrochloride - Google Patents

Novel crystalline form of (3-cyano-1H-indol-7-yl)-[4-(4-fluorophenethyl)-piperazine-1-yl]-methanone hydrochloride Download PDF

Info

Publication number
AU2005289169B2
AU2005289169B2 AU2005289169A AU2005289169A AU2005289169B2 AU 2005289169 B2 AU2005289169 B2 AU 2005289169B2 AU 2005289169 A AU2005289169 A AU 2005289169A AU 2005289169 A AU2005289169 A AU 2005289169A AU 2005289169 B2 AU2005289169 B2 AU 2005289169B2
Authority
AU
Australia
Prior art keywords
crystal form
indol
cyano
fluorophenethyl
preparation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2005289169A
Other languages
English (en)
Other versions
AU2005289169A1 (en
Inventor
Andreas Bathe
Bernd Helfert
Ronald Keiner
Ralf Knierieme
Christoph Saal
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Patent GmbH
Original Assignee
Merck Patent GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent GmbH filed Critical Merck Patent GmbH
Publication of AU2005289169A1 publication Critical patent/AU2005289169A1/en
Application granted granted Critical
Publication of AU2005289169B2 publication Critical patent/AU2005289169B2/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/42—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Anesthesiology (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
AU2005289169A 2004-09-28 2005-09-08 Novel crystalline form of (3-cyano-1H-indol-7-yl)-[4-(4-fluorophenethyl)-piperazine-1-yl]-methanone hydrochloride Ceased AU2005289169B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE102004047517A DE102004047517A1 (de) 2004-09-28 2004-09-28 Neuartige Kristallform von (3-Cyan-1H-indol-7-yl)-[4-(4-fluorphenethyl)-piperazin-1-yl]-methanon, Hydrochlorid
DE102004047517.2 2004-09-28
PCT/EP2005/009647 WO2006034774A1 (de) 2004-09-28 2005-09-08 Neuartige kristallform von (3-cyan-1h-indol-7-yl)-[4-(4-fluorphenethyl)-piperazin-1-yl]-methanon, hydrochlorid

Publications (2)

Publication Number Publication Date
AU2005289169A1 AU2005289169A1 (en) 2006-04-06
AU2005289169B2 true AU2005289169B2 (en) 2011-07-14

Family

ID=35285234

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2005289169A Ceased AU2005289169B2 (en) 2004-09-28 2005-09-08 Novel crystalline form of (3-cyano-1H-indol-7-yl)-[4-(4-fluorophenethyl)-piperazine-1-yl]-methanone hydrochloride

Country Status (16)

Country Link
US (1) US7981897B2 (enExample)
EP (1) EP1794121B1 (enExample)
JP (1) JP5160892B2 (enExample)
KR (1) KR20070057872A (enExample)
CN (1) CN101027284B (enExample)
AR (1) AR051043A1 (enExample)
AU (1) AU2005289169B2 (enExample)
BR (1) BRPI0516200A (enExample)
CA (1) CA2581834A1 (enExample)
DE (1) DE102004047517A1 (enExample)
MX (1) MX2007003471A (enExample)
PE (1) PE20060964A1 (enExample)
RU (1) RU2383532C2 (enExample)
TW (1) TW200616952A (enExample)
WO (1) WO2006034774A1 (enExample)
ZA (1) ZA200703440B (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101437793B (zh) * 2006-05-05 2012-08-22 默克专利股份有限公司 结晶的（3-氰基-1h-吲哚-7-基）-[4-（4-氟苯乙基）哌嗪-1-基]甲酮磷酸盐
CA2652215A1 (en) * 2006-05-05 2007-11-15 Merck Patent Gesellschaft Mit Beschraenkter Haftung Crystalline (3-cyano-1h-indol-7-yl)-[4-(4-fluorophenethyl)piperazin-1-yl]methanone phosphate
MY148643A (en) * 2007-05-11 2013-05-15 Richter Gedeon Nyrt Solvate and crystalline forms of carbamoyl-cyclohexane derivatives
HUP0700353A2 (en) * 2007-05-18 2008-12-29 Richter Gedeon Nyrt Metabolites of (thio)carbamoyl-cyclohexane derivatives
US7875610B2 (en) * 2007-12-03 2011-01-25 Richter Gedeon Nyrt. Pyrimidinyl-piperazines useful as D3/D2 receptor ligands
CA2715760C (en) * 2008-02-21 2017-06-13 Mitsubishi Tanabe Pharma Corporation Solid preparation for oral administration of cariprazine hydrochloride
AU2009270823B2 (en) 2008-07-16 2014-07-17 Richter Gedeon Nyrt. Pharmaceutical formulations containing dopamine receptor ligands
HU230067B1 (hu) 2008-12-17 2015-06-29 Richter Gedeon Nyrt Új piperazin só és eljárás előállítására
HUP0800766A2 (en) 2008-12-18 2010-11-29 Richter Gedeon Vegyeszet Process for the preparation of piperazine derivatives
HUP0800765A2 (en) 2008-12-18 2010-11-29 Richter Gedeon Nyrt A new process for the preparation of piperazine derivatives and their hydrochloric salts
US8912197B2 (en) 2012-08-20 2014-12-16 Forest Laboratories Holdings Ltd. Crystalline form of carbamoyl-cyclohexane derivatives
US11274087B2 (en) 2016-07-08 2022-03-15 Richter Gedeon Nyrt. Industrial process for the preparation of cariprazine
US11547707B2 (en) 2019-04-10 2023-01-10 Richter Gedeon Nyrt. Carbamoyl cyclohexane derivatives for treating autism spectrum disorder

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2084531A1 (en) * 1991-12-19 1993-06-20 David W. Smith Antimigraine 4-pyrimidinyl and pyridinyl derivatives of indol-3yl-alkyl piperazines
DE19934433A1 (de) * 1999-07-22 2001-01-25 Merck Patent Gmbh N-(Indolcarbonyl-)piperazinderivate
DE10102944A1 (de) * 2001-01-23 2002-07-25 Merck Patent Gmbh Verfahren zur Herstellung von (3-Cyan-1H-indol-7-yl)-[4-(4-fluorphenethyl)-piperazin-1-yl]-methanon und dessen Salzen
DE10157673A1 (de) * 2001-11-24 2003-06-05 Merck Patent Gmbh Verwendung von N-(Indolcarbonyl-)piperazinderivaten
DE10246357A1 (de) * 2002-10-04 2004-04-15 Merck Patent Gmbh Verwendung von 5-HT2Rezeptorantagonisten

Also Published As

Publication number Publication date
EP1794121B1 (de) 2013-12-25
MX2007003471A (es) 2007-05-10
CA2581834A1 (en) 2006-04-06
EP1794121A1 (de) 2007-06-13
CN101027284B (zh) 2010-09-29
WO2006034774A1 (de) 2006-04-06
RU2383532C2 (ru) 2010-03-10
US20070259885A1 (en) 2007-11-08
RU2007116037A (ru) 2008-11-10
BRPI0516200A (pt) 2008-08-26
TW200616952A (en) 2006-06-01
CN101027284A (zh) 2007-08-29
KR20070057872A (ko) 2007-06-07
JP2008514558A (ja) 2008-05-08
AU2005289169A1 (en) 2006-04-06
US7981897B2 (en) 2011-07-19
DE102004047517A1 (de) 2006-03-30
ZA200703440B (en) 2008-08-27
AR051043A1 (es) 2006-12-13
PE20060964A1 (es) 2006-10-02
JP5160892B2 (ja) 2013-03-13

Similar Documents

Publication Publication Date Title
JP5714824B2 (ja) １−４−（５−シアノインドール−３−イル）ブチル−４−（２−カルバモイルベンゾフラン−５−イル）ピペラジン塩酸塩の多形相
CA2635834C (en) Trihydrochloride forms of a dihydropteridinone derivative and processes for preparation
EP3098223A1 (en) Crystalline form of a dihydropteridione derivative
US7981897B2 (en) Crystal form of (3-cyano-1H-Indo1-7-yl)-[4-(4-fluorophenethyl)piperazin-1-yl]methanone, hydrochloride
KR20170033684A (ko) 리나글립틴 결정형 및 이의 제조방법
CN102264726A (zh) 新的舒尼替尼盐
JP2005516008A (ja) 結晶［Ｒ−（Ｒ＊，Ｒ＊）］−２−（４−フルオロフェニル）−β，δ−ジヒドロキシ−５−（１−メチルエチル）−３−フェニル−４−［（フェニルアミノ）カルボニル］−１Ｈ−ピロール−ヘプタン酸カルシウム塩（２：１）
JP7168447B2 (ja) ビラスチンの結晶形態及びそれらの調製方法
TWI499584B (zh) ４－｛３－［順－六氫環戊［ｃ］吡咯－２（１ｈ）－基］丙氧基｝苯甲醯胺鹽酸鹽之晶形及其合成方法及含彼之醫藥組合物
KR100572430B1 (ko) 치료적 화합물의 시트르산 염 및 그의 약제학적 조성물
WO2013163917A1 (zh) 化合物jk12a及其制备
HK1105413A (en) Novel crystalline form of (3-cyano-1h-indol-7-yl)-[4-(4-fluorophenethyl)-piperazine-1-yl]-methanon hydrochloride
KR20170060035A (ko) 나트륨 글루코스 공동운반체 2 억제제의 ｌ- 프롤린 화합물, 및 ｌ- 프롤린 화합물의 모노하이드레이트 및 결정
TWI777535B (zh) 用於苯并茚前列腺素之中間物的晶體及其製備方法
AU2007248282B2 (en) Crystalline (3-cyano-1H-indol-7-yl)-[4-(4-fluorophenethyl)piperazin-1-yl]methanone phosphate
CN121270534A (zh) 一种布瑞哌唑-苯甲酸-二水合物的新盐型
RU2772222C2 (ru) Кристаллические формы биластина и способы их получения
JP2008208068A (ja) 塩酸テモカプリルの結晶
WO2017035170A1 (en) Solid state forms of cediranib maleate
TW201319042A (zh) 硫酸卡維地洛的結晶、其製備方法及其在醫藥上的應用
NZ712380B2 (en) Novel abexinostate salt, associated crystalline form, preparation method thereof and the pharmaceutical compositions containing same
NZ712380A (en) Novel abexinostate salt, associated crystalline form, preparation method thereof and the pharmaceutical compositions containing same

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired